{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T14:52:13Z","timestamp":1791989533299,"version":"4.4.0"},"reference-count":322,"publisher":"National Institute for Health and Care Research","issue":"61","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.nationalarchives.gov.uk\/doc\/non-commercial-government-licence\/non-commercial-government-licence.htm"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment programme","doi-asserted-by":"publisher","award":["09\/119\/01"],"award-info":[{"award-number":["09\/119\/01"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Health Technol Assess"],"abstract":"Background<\/jats:title>End-stage renal disease is a long-term irreversible decline in kidney function requiring kidney transplantation, haemodialysis or peritoneal dialysis. The preferred option is kidney transplantation followed by induction and maintenance immunosuppressive therapy to reduce the risk of kidney rejection and prolong graft survival.<\/jats:p><\/jats:sec>Objectives<\/jats:title>To systematically review and update the evidence for the clinical effectiveness and cost-effectiveness of basiliximab (BAS) (Simulect,\u00ae<\/jats:sup>Novartis Pharmaceuticals) and rabbit antihuman thymocyte immunoglobulin (Thymoglobuline,\u00ae<\/jats:sup>Sanofi) as induction therapy and immediate-release tacrolimus [Adoport\u00ae<\/jats:sup>(Sandoz); Capexion\u00ae<\/jats:sup>(Mylan); Modigraf\u00ae<\/jats:sup>(Astellas Pharma); Perixis\u00ae<\/jats:sup>(Accord Healthcare); Prograf\u00ae<\/jats:sup>(Astellas Pharma); Tacni\u00ae<\/jats:sup>(Teva); Vivadex\u00ae<\/jats:sup>(Dexcel Pharma)], prolonged-release tacrolimus (Advagraf,\u00ae<\/jats:sup>Astellas Pharma); belatacept (BEL) (Nulojix,\u00ae<\/jats:sup>Bristol-Myers Squibb), mycophenolate mofetil (MMF) [Arzip\u00ae<\/jats:sup>(Zentiva), CellCept\u00ae<\/jats:sup>(Roche Products), Myfenax\u00ae<\/jats:sup>(Teva), generic MMF is manufactured by Accord Healthcare, Actavis, Arrow Pharmaceuticals, Dr Reddy\u2019s Laboratories, Mylan, Sandoz and Wockhardt], mycophenolate sodium, sirolimus (Rapamune,\u00ae<\/jats:sup>Pfizer) and everolimus (Certican,\u00ae<\/jats:sup>Novartis Pharmaceuticals) as maintenance therapy in children and adolescents undergoing renal transplantation.<\/jats:p><\/jats:sec>Data sources<\/jats:title>Clinical effectiveness searches were conducted to 7 January 2015 in MEDLINE (via Ovid), EMBASE (via Ovid), Cochrane Central Register of Controlled Trials (via Wiley Online Library) and Web of Science [via Institute for Scientific Information (ISI)], Cochrane Database of Systematic Reviews, Database of Abstracts of Reviews of Effects and Health Technology Assessment (HTA) (The Cochrane Library via Wiley Online Library) and Health Management Information Consortium (via Ovid). Cost-effectiveness searches were conducted to 15 January 2015 using a costs or economic literature search filter in MEDLINE (via Ovid), EMBASE (via Ovid), NHS Economic Evaluation Databases (via Wiley Online Library), Web of Science (via ISI), Health Economic Evaluations Database (via Wiley Online Library) and EconLit (via EBSCOhost<\/jats:italic>).<\/jats:p><\/jats:sec>Review methods<\/jats:title>Titles and abstracts were screened according to predefined inclusion criteria, as were full texts of identified studies. Included studies were extracted and quality appraised. Data were meta-analysed when appropriate. A new discrete time state transition economic model (semi-Markov) was developed; graft function, and incidences of acute rejection and new-onset diabetes mellitus were used to extrapolate graft survival. Recipients were assumed to be in one of three health states: functioning graft, graft loss or death.<\/jats:p><\/jats:sec>Results<\/jats:title>Three randomised controlled trials (RCTs) and four non-RCTs were included. The RCTs only evaluated BAS and tacrolimus (TAC). No statistically significant differences in key outcomes were found between BAS and placebo\/no induction. Statistically significantly higher graft function (p<\/jats:italic>\u2009<\u20090.01) and less biopsy-proven acute rejection (odds ratio 0.29, 95% confidence interval 0.15 to 0.57) was found between TAC and ciclosporin (CSA). Only one cost-effectiveness study was identified, which informed NICE guidance TA99. BAS [with TAC and azathioprine (AZA)] was predicted to be cost-effective at \u00a320,000\u201330,000 per quality-adjusted life year (QALY) versus no induction (BAS was dominant). BAS (with CSA and MMF) was not predicted to be cost-effective at \u00a320,000\u201330,000 per QALY versus no induction (BAS was dominated). TAC (with AZA) was predicted to be cost-effective at \u00a320,000\u201330,000 per QALY versus CSA (TAC was dominant). A model based on adult evidence suggests that at a cost-effectiveness threshold of \u00a320,000\u201330,000 per QALY, BAS and TAC are cost-effective in all considered combinations; MMF was also cost-effective with CSA but not TAC.<\/jats:p><\/jats:sec>Limitations<\/jats:title>The RCT evidence is very limited; analyses comparing all interventions need to rely on adult evidence.<\/jats:p><\/jats:sec>Conclusions<\/jats:title>TAC is likely to be cost-effective (vs. CSA, in combination with AZA) at \u00a320,000\u201330,000 per QALY. Analysis based on one RCT found BAS to be dominant, but analysis based on another RCT found BAS to be dominated. BAS plus TAC and AZA was predicted to be cost-effective at \u00a320,000\u201330,000 per QALY when all regimens were compared using extrapolated adult evidence. High-quality primary effectiveness research is needed. The UK Renal Registry could form the basis for a prospective primary study.<\/jats:p><\/jats:sec>Study registration<\/jats:title>This study is registered as PROSPERO CRD42014013544.<\/jats:p><\/jats:sec>Funding<\/jats:title>The National Institute for Health Research HTA programme.<\/jats:p><\/jats:sec>","DOI":"10.3310\/hta20610","type":"journal-article","created":{"date-parts":[[2016,8,24]],"date-time":"2016-08-24T12:55:52Z","timestamp":1472043352000},"page":"1-324","update-policy":"https:\/\/doi.org\/10.3310\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":13,"title":["Immunosuppressive therapy for kidney transplantation in children and adolescents: systematic review and economic evaluation"],"prefix":"10.3310","volume":"20","author":[{"given":"Marcela","family":"Haasova","sequence":"first","affiliation":[{"name":"Peninsula Technology Assessment Group (PenTAG), Evidence Synthesis & Modelling for Health Improvement, University of Exeter, Exeter, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tristan","family":"Snowsill","sequence":"additional","affiliation":[{"name":"Peninsula Technology Assessment Group (PenTAG), Evidence Synthesis & Modelling for Health Improvement, University of Exeter, Exeter, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracey","family":"Jones-Hughes","sequence":"additional","affiliation":[{"name":"Peninsula Technology Assessment Group (PenTAG), Evidence Synthesis & Modelling for Health Improvement, University of Exeter, Exeter, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Crathorne","sequence":"additional","affiliation":[{"name":"Peninsula Technology Assessment Group (PenTAG), Evidence Synthesis & Modelling for Health Improvement, University of Exeter, Exeter, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Cooper","sequence":"additional","affiliation":[{"name":"Peninsula Technology Assessment Group (PenTAG), Evidence Synthesis & Modelling for Health Improvement, University of Exeter, Exeter, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo","family":"Varley-Campbell","sequence":"additional","affiliation":[{"name":"Peninsula Technology Assessment Group (PenTAG), Evidence Synthesis & Modelling for Health Improvement, University of Exeter, Exeter, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Mujica-Mota","sequence":"additional","affiliation":[{"name":"Peninsula Technology Assessment Group (PenTAG), Evidence Synthesis & Modelling for Health Improvement, University of Exeter, Exeter, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Coelho","sequence":"additional","affiliation":[{"name":"Peninsula Technology Assessment Group (PenTAG), Evidence Synthesis & Modelling for Health Improvement, University of Exeter, Exeter, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Huxley","sequence":"additional","affiliation":[{"name":"Peninsula Technology Assessment Group (PenTAG), Evidence Synthesis & Modelling for Health Improvement, University of Exeter, Exeter, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Lowe","sequence":"additional","affiliation":[{"name":"Peninsula Technology Assessment Group (PenTAG), Evidence Synthesis & Modelling for Health Improvement, University of Exeter, Exeter, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Dudley","sequence":"additional","affiliation":[{"name":"Department of Paediatric Nephrology, Bristol Royal Hospital for Children (University Hospitals Bristol NHS Foundation Trust), Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Marks","sequence":"additional","affiliation":[{"name":"Department of Paediatric Nephrology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Hyde","sequence":"additional","affiliation":[{"name":"Peninsula Technology Assessment Group (PenTAG), Evidence Synthesis & Modelling for Health Improvement, University of Exeter, Exeter, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Bond","sequence":"additional","affiliation":[{"name":"Peninsula Technology Assessment Group (PenTAG), Evidence Synthesis & Modelling for Health Improvement, University of Exeter, Exeter, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"Anderson","sequence":"additional","affiliation":[{"name":"Peninsula Technology Assessment Group (PenTAG), Evidence Synthesis & Modelling for Health Improvement, University of Exeter, Exeter, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6221","published-online":{"date-parts":[[2016,8]]},"reference":[{"key":"key20160823140406748_ref1-bib1","volume-title":"Immunosuppressive Therapy for Renal Transplantation in Children and Adolescents; NICE Technology Appraisal Guidance 99","author":"NICE","year":"2006"},{"issue":"49","key":"key20160823140406748_ref1-bib2","doi-asserted-by":"publisher","DOI":"10.3310\/hta10490","article-title":"A systematic review and economic model of the clinical and cost-effectiveness of immunosuppressive therapy for renal transplantation in children","volume":"10","author":"Yao","year":"2006","journal-title":"Health Technol Assess"},{"key":"key20160823140406748_ref1-bib3","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1111\/j.1651-2227.2008.00854.x","article-title":"Children with chronic organ failure possibly ending in organ transplantation: a survey in an Italian region of 5,000,000 inhabitants","volume":"97","author":"Camilla","year":"2008","journal-title":"Acta Paediatr"},{"key":"key20160823140406748_ref1-bib4","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1159\/000370274","article-title":"UK Renal Registry 17th Annual Report: Chapter 4 Demography of the UK Paediatric Renal Replacement Therapy Population in 2013","volume":"129","author":"Pruthi","year":"2015","journal-title":"Nephron"},{"key":"key20160823140406748_ref1-bib5","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1111\/j.1600-6143.2009.02834.x","article-title":"KDIGO clinical practice guideline for the care of kidney transplant recipients","volume":"9","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group","year":"2009","journal-title":"Am J Transplant"},{"key":"key20160823140406748_ref1-bib6","volume-title":"Final Scope: Immunosuppressive Therapy for Kidney Transplantation in Adults (Review of Technology Appraisal Guidance 85)","author":"NICE","year":"2014"},{"key":"key20160823140406748_ref1-bib7","volume-title":"Final Scope: Immunosuppressive Therapy for Kidney Transplantation in Children and Adolescents (Review of Technology Appraisal Guidance 99)","author":"NICE","year":"2014"},{"key":"key20160823140406748_ref1-bib8","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/ncpneph0502","article-title":"Management of growth retardation in pediatric recipients of renal allografts","volume":"3","author":"Fine","year":"2007","journal-title":"Nat Clin Pract Nephrol"},{"key":"key20160823140406748_ref1-bib9","doi-asserted-by":"publisher","first-page":"970946","DOI":"10.1155\/2013\/970946","article-title":"Growth retardation in children with kidney disease","volume":"2013","author":"Salas","year":"2013","journal-title":"Int J Endocrinol"},{"key":"key20160823140406748_ref1-bib10","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1159\/000347024","article-title":"Steroid withdrawal in pediatric kidney transplant allows better growth, lipids and body composition: a randomized controlled trial","volume":"79","author":"Mericq","year":"2013","journal-title":"Horm Res Paediatr"},{"key":"key20160823140406748_ref1-bib11","volume-title":"The National Service Framework for Renal Services. Part One: Dialysis and Transplantation","author":"Department of Health","year":"2004"},{"key":"key20160823140406748_ref1-bib12","volume-title":"Overview of Renal Failure in Children","author":"Berry"},{"key":"key20160823140406748_ref1-bib13","doi-asserted-by":"publisher","first-page":"2","DOI":"10.4103\/0971-4065.62086","article-title":"The evolution of the Banff classification schema for diagnosing renal allograft rejection and its implications for clinicians","volume":"20","author":"Bhowmik","year":"2010","journal-title":"Indian J Nephrol"},{"key":"key20160823140406748_ref1-bib14","volume-title":"When A Transplant Fails. National Kidney Foundation","author":"Tushla"},{"key":"key20160823140406748_ref1-bib15","doi-asserted-by":"publisher","first-page":"3144","DOI":"10.1093\/ndt\/gfh505","article-title":"Modifiable risk factors for non-adherence to immunosuppressants in renal transplant recipients: a cross-sectional study","volume":"19","author":"Butler","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"key20160823140406748_ref1-bib16","volume-title":"Chronic Kidney Disease in Adults: Assessment and Management","author":"NICE","year":"2014"},{"key":"key20160823140406748_ref1-bib17","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1542\/pir.29-10-335","article-title":"Chronic kidney disease in children","volume":"29","author":"Whyte","year":"2008","journal-title":"Pediatr Rev"},{"issue":"38","key":"key20160823140406748_ref1-bib18","doi-asserted-by":"publisher","DOI":"10.3310\/hta13380","article-title":"The effectiveness and cost-effectiveness of methods of storing donated kidneys from deceased donors: a systematic review and economic model","volume":"13","author":"Bond","year":"2009","journal-title":"Health Technol Assess"},{"key":"key20160823140406748_ref1-bib19","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1159\/000236082","article-title":"Diagnostic approach in children with short stature","volume":"72","author":"Oostdijk","year":"2009","journal-title":"Horm Res"},{"key":"key20160823140406748_ref1-bib20","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1007\/s00467-008-0787-0","article-title":"Growth after renal transplantation","volume":"24","author":"Harambat","year":"2009","journal-title":"Pediatr Nephrol"},{"key":"key20160823140406748_ref1-bib21","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/S0022-3476(05)83423-7","article-title":"Factors predictive of sustained growth in children after renal transplantation. The North American Pediatric Renal Transplant Cooperative Study","volume":"122","author":"Tejani","year":"1993","journal-title":"J Pediatr"},{"key":"key20160823140406748_ref1-bib22","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1097\/00007890-199601150-00008","article-title":"Alternate-day steroid dosing improves growth without adversely affecting graft survival or long-term graft function. A report of the North American Pediatric Renal Transplant Cooperative Study","volume":"61","author":"Jabs","year":"1996","journal-title":"Transplantation"},{"key":"key20160823140406748_ref1-bib23","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/00007890-200107150-00006","article-title":"Promising early outcomes with a novel, complete steroid avoidance immunosuppression protocol in pediatric renal transplantation","volume":"72","author":"Sarwal","year":"2001","journal-title":"Transplantation"},{"key":"key20160823140406748_ref1-bib24","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1111\/j.1600-6143.2010.03047.x","article-title":"A randomized trial to assess the impact of early steroid withdrawal on growth in pediatric renal transplantation: the TWIST study","volume":"10","author":"Grenda","year":"2010","journal-title":"Am J Transplant"},{"key":"key20160823140406748_ref1-bib25","volume-title":"NAPRTCS 2010 Annual Transplant Report","author":"North American Pediatric Renal Trials and Collaborative Studies","year":"2010"},{"key":"key20160823140406748_ref1-bib26","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1111\/j.1523-1755.2004.00805.x","article-title":"Effect of renal transplantation in childhood on longitudinal growth and adult height","volume":"66","author":"Nissel","year":"2004","journal-title":"Kidney Int"},{"key":"key20160823140406748_ref1-bib27","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/petr.12173","article-title":"Mortality after pediatric kidney transplantation in England \u2013 a population-based cohort study","volume":"18","author":"Farrugia","year":"2014","journal-title":"Pediatr Transplant"},{"key":"key20160823140406748_ref1-bib28","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1111\/j.1399-3046.2007.00768.x","article-title":"Kidney transplantation in infants and small children","volume":"11","author":"Chavers","year":"2007","journal-title":"Pediatr Transplant"},{"key":"key20160823140406748_ref1-bib29","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.semnephrol.2009.10.009","article-title":"Disparities in kidney transplant outcomes: a review","volume":"30","author":"Gordon","year":"2010","journal-title":"Semin Nephrol"},{"key":"key20160823140406748_ref1-bib30","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/ki.2014.345","article-title":"Racial and ethnic disparities in pediatric renal allograft survival in the United States","volume":"87","author":"Patzer","year":"2015","journal-title":"Kidney Int"},{"key":"key20160823140406748_ref1-bib31","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1111\/j.1600-6143.2005.01019.x","article-title":"Sirolimus in combination with tacrolimus is associated with worse renal allograft survival compared to mycophenolate mofetil combined with tacrolimus","volume":"5","author":"Meier-Kriesche","year":"2005","journal-title":"Am J Transplant"},{"key":"key20160823140406748_ref1-bib32","volume-title":"Annual Report On Kidney Transplantation, Report for 2013\/2014","author":"NHS Blood and Transplant","year":"2014"},{"key":"key20160823140406748_ref1-bib33","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1034\/j.1600-6143.3.s4.11.x","article-title":"Expanded criteria donors for kidney transplantation","volume":"3","author":"Metzger","year":"2003","journal-title":"Am J Transplant"},{"key":"key20160823140406748_ref1-bib34","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1592\/phco.25.5.646.63593","article-title":"Effects of calcineurin inhibitors on sirolimus pharmacokinetics during staggered administration in renal transplant recipients","volume":"25","author":"Wu","year":"2005","journal-title":"Pharmacotherapy"},{"key":"key20160823140406748_ref1-bib35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5812\/nephropathol.8968","article-title":"Psychological impact of chronic kidney disease among children and adolescents: not rare and not benign","volume":"2","author":"Assadi","year":"2013","journal-title":"J Nephropathol"},{"key":"key20160823140406748_ref1-bib36","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1177\/1049732310382789","article-title":"The lived experiences of children and adolescents with end-stage renal disease","volume":"21","author":"Nicholas","year":"2011","journal-title":"Qual Health Res"},{"key":"key20160823140406748_ref1-bib37","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1177\/1359105307078172","article-title":"Living with a kidney transplant \u2013 a qualitative investigation of quality of life","volume":"12","author":"Orr","year":"2007","journal-title":"J Health Psychol"},{"key":"key20160823140406748_ref1-bib38","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/00007890-199107000-00010","article-title":"Long-term quality-of-life after kidney-transplantation in childhood","volume":"52","author":"Morel","year":"1991","journal-title":"Transplantation"},{"key":"key20160823140406748_ref1-bib39","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/j.1399-3046.2005.00356.x","article-title":"Growing pains: non-adherence with the immunosuppressive regimen in adolescent transplant recipients","volume":"9","author":"Dobbels","year":"2005","journal-title":"Pediatr Transplant"},{"key":"key20160823140406748_ref1-bib40","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/j.1399-3046.2007.00811.x","article-title":"A national conference to determine research priorities in pediatric solid organ transplantation","volume":"12","author":"Bartosh","year":"2008","journal-title":"Pediatr Transplant"},{"key":"key20160823140406748_ref1-bib41","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1111\/j.1600-6143.2009.02798.x","article-title":"Transplant outcomes and economic costs associated with patient noncompliance to immunosuppression","volume":"9","author":"Pinsky","year":"2009","journal-title":"Am J Transplant"},{"key":"key20160823140406748_ref1-bib42","volume-title":"Dialysis \u2013 Risks and Side Effects. NHS Choices","author":"NHS"},{"key":"key20160823140406748_ref1-bib43","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1007\/s00467-002-0838-x","article-title":"Growth failure, risk of hospitalization and death for children with end-stage renal disease","volume":"17","author":"Furth","year":"2002","journal-title":"Pediatr Nephrol"},{"key":"key20160823140406748_ref1-bib44","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1016\/S0031-3955(03)00128-7","article-title":"Psychosocial adaptation after solid organ transplantation in children","volume":"50","author":"Qvist","year":"2003","journal-title":"Pediatr Clin North Am"},{"key":"key20160823140406748_ref1-bib45","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1097\/01.TP.0000120947.75697.8B","article-title":"Long-term social outcome of children after kidney transplantation","volume":"77","author":"Broyer","year":"2004","journal-title":"Transplantation"},{"key":"key20160823140406748_ref1-bib46","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1080\/08860220601098862","article-title":"Quality of life in CAPD, transplant, and chronic renal failure patients with diabetes","volume":"29","author":"Apostolou","year":"2007","journal-title":"Renal Failure"},{"key":"key20160823140406748_ref1-bib47","first-page":"521","article-title":"Changes in health-related quality of life in Greek adult patients 1 year after successful renal transplantation","volume":"4","author":"Balaska","year":"2006","journal-title":"Exp Clin Transplant"},{"key":"key20160823140406748_ref1-bib48","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1185\/030079908X253410","article-title":"Utility of health states in chronic kidney disease: a structured review of the literature","volume":"24","author":"Dale","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"key20160823140406748_ref1-bib49","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/j.transproceed.2007.03.004","article-title":"Pain affects health-related quality of life in kidney transplant recipients","volume":"39","author":"Nourbala","year":"2007","journal-title":"Transplant Proc"},{"key":"key20160823140406748_ref1-bib50","first-page":"500","article-title":"Quality-of-life for patients in an end-stage renal-disease program","volume":"71","author":"Seedat","year":"1987","journal-title":"S Afr Med J"},{"key":"key20160823140406748_ref1-bib51","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/j.1399-0012.2005.00433.x","article-title":"Quality of life after organ transplantation in type 1 diabetics with end-stage renal disease","volume":"20","author":"Sureshkumar","year":"2006","journal-title":"Clin Transplant"},{"key":"key20160823140406748_ref1-bib52","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1016\/j.transproceed.2004.09.019","article-title":"Changes in quality of life after renal transplantation","volume":"37","author":"Overbeck","year":"2005","journal-title":"Transplant Proc"},{"key":"key20160823140406748_ref1-bib53","volume-title":"Kidney Disease: Key Facts and Figures","author":"NHS Kidney Care","year":"2010"},{"key":"key20160823140406748_ref1-bib54","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S0168-8510(98)00017-7","article-title":"Economic evaluation of end stage renal disease treatment","volume":"44","author":"de Wit","year":"1998","journal-title":"Health Policy"},{"key":"key20160823140406748_ref1-bib55","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1111\/j.1600-6143.2004.00535.x","article-title":"Diminishing significance of HLA matching in kidney transplantation","volume":"4","author":"Su","year":"2004","journal-title":"Am J Transplant"},{"key":"key20160823140406748_ref1-bib56","volume-title":"United Kingdom Guidelines: Management of The Failing Kidney Transplant. The British Transplantation Society","author":"Working Party of The British Transplantation Society","year":"2013"},{"key":"key20160823140406748_ref1-bib57","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1093\/ndt\/gfs269","article-title":"Estimating the financial cost of chronic kidney disease to the NHS in England","volume":"27","author":"Kerr","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"key20160823140406748_ref1-bib58","volume-title":"NHS Reference Costs 2013 to 2014","author":"Department of Health","year":"2014"},{"key":"key20160823140406748_ref1-bib59","doi-asserted-by":"publisher","first-page":"C311","DOI":"10.1159\/000328074","article-title":"Renal association clinical practice guideline on post-operative care of the kidney transplant recipient","volume":"118","author":"Baker","year":"2011","journal-title":"Nephron Clinical Practice"},{"key":"key20160823140406748_ref1-bib60","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1097\/01.tp.0000438205.04348.69","article-title":"The Economic Burden of Posttransplant Events in Renal Transplant Recipients in Europe","volume":"97","author":"Chamberlain","year":"2014","journal-title":"Transplantation"},{"key":"key20160823140406748_ref1-bib61","volume-title":"Surface Area of the Human Body","author":"Boyd","year":"1935"},{"key":"key20160823140406748_ref1-bib62","volume-title":"eMIT National Database (2014\/06). Drugs and Pharmaceutical Electronic Market Information (eMIT)","author":"Commercial Medicines Unit","year":"2014"},{"key":"key20160823140406748_ref1-bib63","volume-title":"British National Formulary","author":"Joint Formulary Committee","year":"2014","edition":"68th ed."},{"key":"key20160823140406748_ref1-bib64","volume-title":"Cyclosporine Dosage Guide with Precautions - Drugs.com","author":"Drugs.com","year":"2015"},{"key":"key20160823140406748_ref1-bib65","volume-title":"Anti-Thymocyte Globulin (Rabbit) Dosage Guide with Precautions \u2013 Drugs.com","author":"Drugs.com","year":"2015"},{"key":"key20160823140406748_ref1-bib66","volume-title":"Immunosuppressive therapy for kidney transplantation in adults (review of technology appraisal guidance 85); Belatacept submission of evidence","author":"Bristol Myers Squibb","year":"2014"},{"key":"key20160823140406748_ref1-bib67","volume-title":"Protocol: Immunosuppressive Therapy for Kidney Transplantation in Children and Adolescents (Review of Technology Appraisal Guidance TA99)","author":"NICE","year":"2014"},{"key":"key20160823140406748_ref1-bib68","doi-asserted-by":"crossref","DOI":"10.3310\/hta20620","article-title":"Immunosuppressive therapy for kidney transplantation in adults (review of technology appraisal guidance 85); a systematic review and economic model","author":"Jones-Hughes","year":"2016","journal-title":"Health Technol Assess"},{"key":"key20160823140406748_ref1-bib69","volume-title":"Systematic Reviews: CRD\u2019s Guidance for Undertaking Reviews in Healthcare","author":"Centre for Reviews and Dissemination","year":"2009"},{"issue":"27","key":"key20160823140406748_ref1-bib70","doi-asserted-by":"publisher","DOI":"10.3310\/hta7270","article-title":"Evaluating non-randomised intervention studies","volume":"7","author":"Deeks","year":"2003","journal-title":"Health Technol Assess"},{"key":"key20160823140406748_ref1-bib71","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2011"},{"key":"key20160823140406748_ref1-bib72","first-page":"155","article-title":"Long-term results after induction therapy with Basiliximab in pediatric renal transplantation","volume":"13","author":"Jungraithmayr","year":"2009","journal-title":"Pediatr Transplant"},{"key":"key20160823140406748_ref1-bib73","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1097\/TP.0b013e318188af15","article-title":"Efficacy and safety of basiliximab in pediatric renal transplant patients receiving cyclosporine, mycophenolate mofetil, and steroids","volume":"86","author":"Offner","year":"2008","journal-title":"Transplantation"},{"key":"key20160823140406748_ref1-bib74","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1097\/TP.0b013e318188ae18","article-title":"Pharmacokinetics and immunodynamics of basiliximab in pediatric renal transplant recipients on mycophenolate mofetil comedication","volume":"86","author":"H\u00f6cker","year":"2008","journal-title":"Transplantation"},{"key":"key20160823140406748_ref1-bib75","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1111\/j.1600-6143.2006.01367.x","article-title":"A prospective, randomized, multicenter trial of tacrolimus-based therapy with or without basiliximab in pediatric renal transplantation","volume":"6","author":"Grenda","year":"2006","journal-title":"Am J Transplant"},{"key":"key20160823140406748_ref1-bib76","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s00467-008-0931-x","article-title":"Multicentre prospective randomised trial of tacrolimus, azathioprine and prednisolone with or without basiliximab: two-year follow-up data","volume":"24","author":"Webb","year":"2009","journal-title":"Pediatric Nephrology"},{"key":"key20160823140406748_ref1-bib77","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00467-001-0795-9","article-title":"Randomized trial of tracolimus versus cyclosporin microemulsion in renal transplantation","volume":"17","author":"Trompeter","year":"2002","journal-title":"Pediatric Nephrology"},{"key":"key20160823140406748_ref1-bib78","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1016\/S0041-1345(02)03128-7","article-title":"One-year glomerular filtration rate predicts graft survival in pediatric renal recipients: a randomized trial of tacrolimus vs cyclosporine microemulsion","volume":"34","author":"Filler","year":"2002","journal-title":"Transplant Proc"},{"key":"key20160823140406748_ref1-bib79","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1111\/j.1399-3046.2005.00334.x","article-title":"Four-year data after pediatric renal transplantation: a randomized trial of tacrolimus vs. cyclosporin microemulsion","volume":"9","author":"Filler","year":"2005","journal-title":"Pediatr Transplant"},{"key":"key20160823140406748_ref1-bib80","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1016\/S0041-1345(02)03475-9","article-title":"Pediatric renal transplantation under tacrolimus or cyclosporine immunosuppression and basiliximab induction","volume":"34","author":"Garcia","year":"2002","journal-title":"Transplant Proc"},{"key":"key20160823140406748_ref1-bib81","doi-asserted-by":"publisher","first-page":"4085","DOI":"10.1016\/S0041-1345(98)01350-5","article-title":"Comparison between mycophenolate mofetil and azathioprine based immunosuppression in pediatric renal transplantation from living related donors","volume":"30","author":"Antoniadis","year":"1998","journal-title":"Transplant Proc"},{"key":"key20160823140406748_ref1-bib82","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1034\/j.1399-3046.1999.00003.x","article-title":"Mycophenolate mofetil in pediatric renal transplantation","volume":"3","author":"Benfield","year":"1999","journal-title":"Pediatr Transplant"},{"key":"key20160823140406748_ref1-bib83","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1097\/00007890-200103150-00010","article-title":"Mycophenolate mofetil in pediatric renal transplantation without induction therapy: results after 12 months of treatment. German Pediatric Renal Transplantation Study Group","volume":"71","author":"Staskewitz","year":"2001","journal-title":"Transplantation"},{"key":"key20160823140406748_ref1-bib84","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1097\/01.TP.0000045748.95874.64","article-title":"Pediatric renal transplantation with mycophenolate mofetil-based immunosuppression without induction: results after three years","volume":"75","author":"Jungraithmayr","year":"2003","journal-title":"Transplantation"},{"key":"key20160823140406748_ref1-bib85","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1097\/01.tp.0000258587.70166.87","article-title":"Five-year outcome in pediatric patients with mycophenolate mofetil-based renal transplantation","volume":"83","author":"Jungraithmayr","year":"2007","journal-title":"Transplantation"},{"key":"key20160823140406748_ref1-bib86","first-page":"328","article-title":"Design of a randomized study evaluating everolimus in pediatric renal transplant recipients","volume":"26","author":"Gupta","year":"2013","journal-title":"Transplant International"},{"key":"key20160823140406748_ref1-bib87","first-page":"80","article-title":"Evaluation of safety and efficacy of everolimus with reduced tacrolimus: design of a randomized, multicenter, open-label study in pediatric renal transplant recipients","volume":"17","author":"Langer","year":"2013","journal-title":"Pediatr Transplant"},{"key":"key20160823140406748_ref1-bib88","first-page":"328","article-title":"Design of crad001a2314: a randomised study evaluating everolimus in paediatric renal transplantation","volume":"26","author":"Tonshoff","year":"2013","journal-title":"Transplant International"},{"key":"key20160823140406748_ref1-bib89","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1097\/00007890-201211271-02397","article-title":"Early conversion of calcineurin inhibitor to everolimus in de novo paediatric renal transplant recipients and its impact on efficacy and renal function; design of an open-label, randomised, multi-centre study","volume":"94","author":"Tonshoff","year":"2012","journal-title":"Transplantation"},{"key":"key20160823140406748_ref1-bib90","unstructured":"Grenda R, Watson A, Vondrak K, Webb NJ, Beattie J. Tacrolimus Triple Therapy With or Without Monoclonal Antibody Administration: A Multicentre, Randomised Study in Paediatric Kidney Transplantation. 3rd International Congress on Immunosuppression, 8\u201311 December 2004, San Diego, CA, abstract no. 94."},{"key":"key20160823140406748_ref1-bib91","doi-asserted-by":"publisher","first-page":"2878","DOI":"10.1016\/j.transproceed.2003.10.087","article-title":"Triple immunosuppression with or without basiliximab in pediatric renal transplantation: acute rejection rates at one year","volume":"35","author":"Duzova","year":"2003","journal-title":"Transplant Proc"},{"key":"key20160823140406748_ref1-bib92","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1093\/ndt\/17.2.276","article-title":"Single centre experience with basiliximab in paediatric renal transplantation","volume":"17","author":"Pape","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"key20160823140406748_ref1-bib93","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s004670100642","article-title":"Basiliximab induction improves the outcome of renal transplants in children and adolescents","volume":"16","author":"Swiatecka-Urban","year":"2001","journal-title":"Pediatr Nephrol"},{"key":"key20160823140406748_ref1-bib94","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1034\/j.1399-3046.2003.00079.x","article-title":"Tacrolimus vs. cyclosporine A as primary immunosuppression in pediatric renal transplantation: a NAPRTCS study","volume":"7","author":"Neu","year":"2003","journal-title":"Pediatr Transplant"},{"key":"key20160823140406748_ref1-bib95","first-page":"651a","article-title":"Mycophenolate mofetil (MMF) versus azathioprine (AZA) in a large registry of pediatric renal transplant patients","volume":"14","author":"Steffen","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"key20160823140406748_ref1-bib96","volume-title":"Statistical Methodology and Risk-adjustment for Survival Rate Estimation","author":"UK Transplant Registry","year":"2011"},{"key":"key20160823140406748_ref1-bib97","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1097\/TP.0b013e3182a203bd","article-title":"OSAKA trial: a randomized, controlled trial comparing tacrolimus QD and BD in kidney transplantation","volume":"96","author":"Albano","year":"2013","journal-title":"Transplantation"},{"key":"key20160823140406748_ref1-bib98","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1097\/01.tp.0000268084.64888.f3","article-title":"Single bolus antithymocyte globulin versus basiliximab induction in kidney transplantation with cyclosporine triple immunosuppression: efficacy and safety","volume":"84","author":"Kyll\u00f6nen","year":"2007","journal-title":"Transplantation"},{"key":"key20160823140406748_ref1-bib99","first-page":"393","article-title":"Basiliximab reduces the incidence of acute cellular rejection in live-related-donor kidney transplantation: a three-year prospective randomized trial","volume":"16","author":"Sheashaa","year":"2003","journal-title":"J Nephrol"},{"key":"key20160823140406748_ref1-bib100","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1097\/00007890-199901270-00016","article-title":"Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody","volume":"67","author":"Kahan","year":"1999","journal-title":"Transplantation"},{"key":"key20160823140406748_ref1-bib101","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1016\/S0140-6736(97)09278-7","article-title":"Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients","volume":"350","author":"Nashan","year":"1997","journal-title":"Lancet"},{"key":"key20160823140406748_ref1-bib102","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1097\/00007890-200110150-00014","article-title":"A randomized, double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients","volume":"72","author":"Ponticelli","year":"2001","journal-title":"Transplantation"},{"key":"key20160823140406748_ref1-bib103","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1097\/00007890-200301150-00007","article-title":"Randomized double-blind study of immunoprophylaxis with basiliekimab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetil-containing triple therapy in renal transplantation","volume":"75","author":"Lawen","year":"2003","journal-title":"Transplantation"},{"key":"key20160823140406748_ref1-bib104","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/S0041-1345(02)03769-7","article-title":"Randomised trial of simulect versus placebo for control of acute rejection in renal allograft recipients","volume":"35","author":"Bingyi","year":"2003","journal-title":"Transplant Proc"},{"key":"key20160823140406748_ref1-bib105","first-page":"86","article-title":"FK 506 versus cyclosporin in the prevention of renal allograft rejection--European pilot study: six-week results","volume":"8","author":"Schleibner","year":"1995","journal-title":"Transpl Int"},{"key":"key20160823140406748_ref1-bib106","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1097\/00007890-199610150-00005","article-title":"An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: a report of the United States Multicenter FK506 Kidney Transplant Group","volume":"62","author":"Laskow","year":"1996","journal-title":"Transplantation"},{"key":"key20160823140406748_ref1-bib107","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1097\/00007890-199708150-00012","article-title":"Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group","volume":"64","author":"Mayer","year":"1997","journal-title":"Transplantation"},{"key":"key20160823140406748_ref1-bib108","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1111\/j.1432-2277.2004.00055.x","article-title":"Long-term results of a prospective randomized trial comparing tacrolimus versus cyclosporine in African-American recipients of primary cadaver renal transplant","volume":"18","author":"Jarzembowski","year":"2005","journal-title":"Transplant Int"},{"key":"key20160823140406748_ref1-bib109","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1016\/S0041-1345(02)02968-8","article-title":"One-year follow-up of a Brazilian randomized multicenter study comparing tacrolimus versus cyclosporine in kidney transplantation","volume":"34","author":"Campos","year":"2002","journal-title":"Transplant Proc"},{"key":"key20160823140406748_ref1-bib110","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S0140-6736(02)07875-3","article-title":"Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomised multicentre study","volume":"359","author":"Margreiter","year":"2002","journal-title":"Lancet"},{"key":"key20160823140406748_ref1-bib111","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1016\/S0041-1345(02)03033-6","article-title":"Primary immunosuppression with tacrolimus is associated with a reduction in renal allograft fibrosis compared with neoral therapy","volume":"34","author":"Waller","year":"2002","journal-title":"Transplant Proc"},{"key":"key20160823140406748_ref1-bib112","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1097\/01.TP.0000056635.59888.EF","article-title":"A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients","volume":"75","author":"Charpentier","year":"2003","journal-title":"Transplantation"},{"key":"key20160823140406748_ref1-bib113","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1097\/01.TP.0000162980.68628.5A","article-title":"A randomized, prospective, pharmacoeconomic trial of tacrolimus versus cyclosporine in combination with thymoglobulin in renal transplant recipients","volume":"80","author":"Hardinger","year":"2005","journal-title":"Transplantation"},{"key":"key20160823140406748_ref1-bib114","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1111\/j.1600-6143.2006.01407.x","article-title":"Post-transplant sCD30 and neopterin as predictors of chronic allograft nephropathy: impact of different immunosuppressive regimens","volume":"6","author":"Weimer","year":"2006","journal-title":"Am J Transplant"},{"key":"key20160823140406748_ref1-bib115","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1097\/00007890-199604150-00008","article-title":"A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group","volume":"61","author":"Tricontinental MMF renal study","year":"1996","journal-title":"Transplantation"},{"key":"key20160823140406748_ref1-bib116","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1097\/00007890-200208270-00013","article-title":"Short\u2013term combination of mycophenolate mofetil with cyclosporine as a therapeutic option for renal transplant recipients: a prospective, multicenter, randomized study","volume":"74","author":"Sadek","year":"2002","journal-title":"Transplantation"},{"key":"key20160823140406748_ref1-bib117","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1111\/j.1600-6143.2004.00533.x","article-title":"Lower incidence of chronic allograft nephropathy at 1 year post-transplantation in patients treated with mycophenolate mofetil","volume":"4","author":"Merville","year":"2004","journal-title":"Am J Transplant"},{"key":"key20160823140406748_ref1-bib118","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1016\/S0041-1345(02)02861-0","article-title":"Mycophenolate mofetil in renal transplantation: five years experience","volume":"34","author":"Tuncer","year":"2002","journal-title":"Transplant Proc"},{"key":"key20160823140406748_ref1-bib119","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1681\/ASN.2006101153","article-title":"Mycophenolate mofetil versus azathioprine for prevention of chronic allograft dysfunction in renal transplantation: the MYSS follow-up randomized, controlled clinical trial","volume":"18","author":"Remuzzi","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"key20160823140406748_ref1-bib120","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1097\/00007890-199508000-00003","article-title":"Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group","volume":"60","author":"Sollinger","year":"1995","journal-title":"Transplantation"},{"key":"key20160823140406748_ref1-bib121","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1046\/j.1523-1755.2002.00149.x","article-title":"Molecular and structural consequences of early renal allograft injury","volume":"61","author":"Baboolal","year":"2002","journal-title":"Kidney Int"},{"key":"key20160823140406748_ref1-bib122","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/s0041-1345(02)03033-6","article-title":"Primary immunosuppression with tacrolimus is associated with reduction in renal allograft fibrosis compared with neoral therapy","volume":"17","author":"Waller","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"key20160823140406748_ref1-bib123","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1681\/ASN.V131213","article-title":"Glucose metabolism in the first 3 years after renal transplantation in patients receiving tacrolimus versus cyclosporine-based immunosuppression","volume":"13","author":"van Duijnhoven","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"key20160823140406748_ref1-bib124","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1432-2277.1998.tb00948.x","article-title":"Pronounced renal vasoconstriction and systemic hypertension in renal transplant patients treated with cyclosporin A versus FK 506","volume":"11","author":"Radermacher","year":"1998","journal-title":"Transpl Int"},{"key":"key20160823140406748_ref1-bib125","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/S0041-1345(98)01929-0","article-title":"Tacrolimus\/\u2018low-dose\u2019 mycophenolate mofetil versus microemulsion cyclosporine\/\u2018low-dose\u2019 mycophenolate mofetil after kidney transplantation\u20131-year follow-up of a prospective, randomized clinical trial","volume":"31","author":"Yang","year":"1999","journal-title":"Transplant Proc"},{"key":"key20160823140406748_ref1-bib126","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S0929-6646(08)60166-7","article-title":"Favorable results of concomitant tacrolimus and sirolimus therapy in Taiwanese renal transplant recipients at 12 months","volume":"107","author":"Chen","year":"2008","journal-title":"J Formos Med Assoc"},{"key":"key20160823140406748_ref1-bib127","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1056\/NEJMoa067411","article-title":"Reduced exposure to calcineurin inhibitors in renal transplantation","volume":"357","author":"Ekberg","year":"2007","journal-title":"N Engl J Med"},{"key":"key20160823140406748_ref1-bib128","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1097\/TP.0b013e3181db09e4","article-title":"Thymoglobulin induction and sirolimus versus tacrolimus in kidney transplant recipients receiving mycophenolate mofetil and steroids","volume":"89","author":"Glotz","year":"2010","journal-title":"Transplantation"},{"key":"key20160823140406748_ref1-bib129","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/j.1600-6143.2010.03338.x","article-title":"Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients","volume":"11","author":"Ferguson","year":"2011","journal-title":"Am J Transplant"},{"key":"key20160823140406748_ref1-bib130","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1017\/S0266462305050324","article-title":"Criteria list for assessment of methodological quality of economic evaluations: consensus on health economic criteria","volume":"21","author":"Evers","year":"2005","journal-title":"Int J Technol Assess Health Care"},{"issue":"36","key":"key20160823140406748_ref1-bib131","doi-asserted-by":"publisher","DOI":"10.3310\/hta8360","article-title":"Review of guidelines for good practice in decision-analytic modelling in health technology assessment","volume":"8","author":"Philips","year":"2004","journal-title":"Health Technol Assess"},{"key":"key20160823140406748_ref1-bib132","doi-asserted-by":"publisher","first-page":"355","DOI":"10.2165\/00019053-200624040-00006","article-title":"Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment","volume":"24","author":"Philips","year":"2006","journal-title":"Pharmacoeconomics"},{"key":"key20160823140406748_ref1-bib133","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/1477-7525-10-139","article-title":"Characterizing the relationship between health utility and renal function after kidney transplantation in UK and US: a cross-sectional study","volume":"10","author":"Neri","year":"2012","journal-title":"Health Qual Life Outcomes"},{"key":"key20160823140406748_ref1-bib134","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1111\/j.1600-6143.2012.04013.x","article-title":"Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant","volume":"12","author":"Wiebe","year":"2012","journal-title":"Am J Transplant"},{"key":"key20160823140406748_ref1-bib135","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1097\/TP.0b013e3182725532","article-title":"Improved adherence to tacrolimus once-daily formulation in renal recipients: a randomized controlled trial using electronic monitoring","volume":"95","author":"Kuypers","year":"2013","journal-title":"Transplantation"},{"key":"key20160823140406748_ref1-bib136","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1097\/TP.0b013e3182292426","article-title":"Lower Variability of Tacrolimus Trough Concentration After Conversion From Prograf to Advagraf in Stable Kidney Transplant Recipients","volume":"92","author":"Wu","year":"2011","journal-title":"Transplantation"},{"key":"key20160823140406748_ref1-bib137","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.1093\/ndt\/gfq096","article-title":"High within-patient variability in the clearance of tacrolimus is a risk factor for poor long-term outcome after kidney transplantation","volume":"25","author":"Borra","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"key20160823140406748_ref1-bib138","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1034\/j.1600-6143.2003.00010.x","article-title":"Diabetes mellitus after kidney transplantation in the United States","volume":"3","author":"Kasiske","year":"2003","journal-title":"Am J Transplant"},{"key":"key20160823140406748_ref1-bib139","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1111\/j.1600-6143.2010.03256.x","article-title":"Tacrolimus once daily (ADVAGRAF) versus twice daily (PROGRAF) in de novo renal transplantation: a randomized phase III study","volume":"10","author":"Kr\u00e4mer","year":"2010","journal-title":"Am J Transplant"},{"key":"key20160823140406748_ref1-bib140","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1016\/j.transproceed.2008.03.090","article-title":"Patient outcomes and economics of once-daily tacrolimus in renal transplant patients: results of a modeling analysis","volume":"40","author":"Abecassis","year":"2008","journal-title":"Transplant Proc"},{"key":"key20160823140406748_ref1-bib141","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1016\/S0041-1345(02)02964-0","article-title":"A cost-effectiveness analysis of tacrolimus versus cyclosporine microemulsion following kidney transplantation","volume":"34","author":"Craig","year":"2002","journal-title":"Transplant Proc"},{"key":"key20160823140406748_ref1-bib142","first-page":"580","article-title":"Tacrolimus versus cyclosporin in renal transplantation in Italy: cost-minimisation and cost-effectiveness analyses","volume":"15","author":"Lazzaro","year":"2002","journal-title":"J Nephrol"},{"key":"key20160823140406748_ref1-bib143","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.2165\/00019053-200321170-00003","article-title":"The cost effectiveness of tacrolimus versus microemulsified cyclosporin: a 10-year model of renal transplantation outcomes","volume":"21","author":"Orme","year":"2003","journal-title":"Pharmacoeconomics"},{"key":"key20160823140406748_ref1-bib144","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1681\/ASN.2007040495","article-title":"Lifetime cost-effectiveness of calcineurin inhibitor withdrawal after de novo renal transplantation","volume":"19","author":"Earnshaw","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"key20160823140406748_ref1-bib145","doi-asserted-by":"publisher","first-page":"67","DOI":"10.2165\/00019053-200624010-00006","article-title":"Evaluation of the cost effectiveness of sirolimus versus tacrolimus for immunosuppression following renal transplantation in the UK","volume":"24","author":"McEwan","year":"2006","journal-title":"Pharmacoeconomics"},{"key":"key20160823140406748_ref1-bib146","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s10198-009-0148-3","article-title":"Cost-effectiveness of immunosuppressive regimens in renal transplant recipients in Germany: a model approach","volume":"11","author":"Jurgensen","year":"2010","journal-title":"Eur J Health Econ"},{"key":"key20160823140406748_ref1-bib147","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s10198-014-0579-3","article-title":"Cost-effectiveness of modern mTOR inhibitor based immunosuppression compared to the standard of care after renal transplantation in Germany","volume":"16","author":"Jurgensen","year":"2015","journal-title":"Eur J Health Econ"},{"key":"key20160823140406748_ref1-bib148","doi-asserted-by":"publisher","first-page":"3367","DOI":"10.1016\/j.transproceed.2011.09.092","article-title":"Cost-effectiveness analysis of the early conversion of tacrolimus to mammalian target of rapamycin inhibitors in patients with renal transplantation","volume":"43","author":"Gamboa","year":"2011","journal-title":"Transplant Proc"},{"key":"key20160823140406748_ref1-bib149","doi-asserted-by":"publisher","first-page":"A156","DOI":"10.1016\/j.jval.2012.03.840","article-title":"Cost-utility assessment of sirolimus versus tacrolimus for primary prevention of graft rejection in renal transplant recipients in Mexico","volume":"15","author":"Rely","year":"2012","journal-title":"Value Health"},{"key":"key20160823140406748_ref1-bib150","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.transproceed.2005.11.092","article-title":"Economic evaluation of sirolimus-based immunosuppressive regimens in kidney graft recipients","volume":"38","author":"Niemczyk","year":"2006","journal-title":"Transplant Proc"},{"key":"key20160823140406748_ref1-bib151","first-page":"1537","article-title":"Cost utility analysis of immunosuppressive regimens in adult renal transplant recipients in England and Wales","volume":"8","author":"Muduma","year":"2014","journal-title":"Patient Prefer Adherence"},{"key":"key20160823140406748_ref1-bib152","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1111\/j.1600-6143.2007.01661.x","article-title":"One-year results with extended-release tacrolimus\/MMF, tacrolimus\/MMF and cyclosporine\/MMF in de novo kidney transplant recipients","volume":"7","author":"Silva","year":"2007","journal-title":"Am J Transplant"},{"key":"key20160823140406748_ref1-bib153","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1097\/TP.0b013e3181661695","article-title":"Collaborative Transplant Study Report. Influence of time of rejection on long-term graft survival in renal transplantation","volume":"85","author":"Opelz","year":"2008","journal-title":"Transplantation"},{"key":"key20160823140406748_ref1-bib154","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1159\/000360027","article-title":"UK Renal Registry 16th Annual Report: chapter 8 Survival and Cause of Death of UK Adult Patients on Renal Replacement Therapy in 2012: National and Centre-specific Analyses","volume":"125","author":"Pruthi","year":"2013","journal-title":"Nephron Clinical Practice"},{"key":"key20160823140406748_ref1-bib155","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1016\/j.clinthera.2005.11.002","article-title":"Evaluation of the cost-effectiveness of sirolimus versus cyclosporin for immunosuppression after renal transplantation in the United Kingdom","volume":"27","author":"McEwan","year":"2005","journal-title":"Clin Ther"},{"key":"key20160823140406748_ref1-bib156","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.cd004290.pub2","article-title":"Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients","volume":"2","author":"Webster","year":"2006","journal-title":"Cochrane Database System Rev"},{"key":"key20160823140406748_ref1-bib157","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1681\/ASN.2009111109","article-title":"Five-year safety and efficacy of belatacept in renal transplantation","volume":"21","author":"Vincenti","year":"2010","journal-title":"J Am Soc Nephrol"},{"issue":"iii","key":"key20160823140406748_ref1-bib158","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1097\/00007890-201007272-00303","article-title":"Belatacept vs cyclosporine in ECD kidney transplants: two-year outcomes from the BENEFIT-EXT study","volume":"3","author":"Durrbach","year":"2010","journal-title":"NDT Plus"},{"key":"key20160823140406748_ref1-bib159","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1185\/030079905X65277","article-title":"Characterisation and comparison of health-related quality of life for patients with renal failure","volume":"21","author":"Lee","year":"2005","journal-title":"Curr Med Res Opin"},{"key":"key20160823140406748_ref1-bib160","volume-title":"School Age Charts and Resources Boys 2\u201318 Years","author":"Royal College of Paediatrics and Child Health"},{"key":"key20160823140406748_ref1-bib161","volume-title":"School Age Charts and Resources, Girls 2\u201318 Years","author":"Royal College of Paediatrics and Child Health"},{"key":"key20160823140406748_ref1-bib162","volume-title":"British National Formulary","author":"Joint Formulary Committee","year":"2014"},{"key":"key20160823140406748_ref1-bib163","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1111\/j.1399-3046.2007.00832.x","article-title":"Multicenter trial of everolimus in pediatric renal transplant recipients: results at three year","volume":"12","author":"Ettenger","year":"2008","journal-title":"Pediatr Transplant"},{"key":"key20160823140406748_ref1-bib164","volume-title":"NHS Electronic Drug Tariff 2014","author":"NHS"},{"key":"key20160823140406748_ref1-bib165","volume-title":"Guide to the Methods of Technology Appraisal 2013","author":"NICE","year":"2013"},{"key":"key20160823140406748_ref1-bib166","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1093\/ndt\/gfm870","article-title":"The cost of renal dialysis in a UK setting--a multicentre study","volume":"23","author":"Baboolal","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"key20160823140406748_ref1-bib167","volume-title":"NHS Reference Costs \u2013 Renal Transplant and Dialysis","author":"NHS","year":"2013"},{"key":"key20160823140406748_ref1-bib168","volume-title":"Belatacept (Nulojix\u00ae)","author":"All Wales Medicines Strategy Group","year":"2012"},{"issue":"8","key":"key20160823140406748_ref1-bib169","doi-asserted-by":"publisher","DOI":"10.3310\/hta13080","article-title":"The use of surrogate outcomes in model-based cost-effectiveness analyses: a survey of UK Health Technology Assessment reports","volume":"13","author":"Taylor","year":"2009","journal-title":"Health Technol Assess"},{"key":"key20160823140406748_ref1-bib170","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.paed.2012.04.001","article-title":"Paediatric renal transplantation","volume":"22","author":"Williams","year":"2012","journal-title":"Paediatr Child Health"},{"key":"key20160823140406748_ref1-bib171","volume-title":"Introduction to Payment by Results","author":"Health and Social Care Information Centre"},{"key":"key20160823140406748_ref1-bib172","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1159\/000360026","article-title":"UK Renal Registry 16th annual report: chapter 7 demography of the UK paediatric renal replacement therapy population in 2012","volume":"125","author":"Pruthi","year":"2013","journal-title":"Nephron Clinical Practice"},{"key":"key20160823140406748_ref1-bib173","volume-title":"British National Formulary for Children","author":"Joint Formulary Committee","year":"2014","edition":"68 ed."},{"key":"key20160823140406748_ref1-bib174","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1054\/bjoc.2001.1859","article-title":"Body surface area estimation in children using weight alone: application in paediatric oncology","volume":"85","author":"Sharkey","year":"2001","journal-title":"Br J Cancer"},{"key":"key20160823140406748_ref1-bib175","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1159\/000360022","article-title":"UK Renal Registry 16th Annual Report: chapter 3 Demographic and biochemistry profile of kidney transplant recipients in the UK in 2012: national and centre-specific analyses","volume":"125","author":"Pruthi","year":"2013","journal-title":"Nephron Clinical Practice"},{"key":"key20160823140406748_ref1-bib176","doi-asserted-by":"publisher","first-page":"3031","DOI":"10.1111\/j.1600-6143.2012.04226.x","article-title":"Association of HLA mismatch with death with a functioning graft after kidney transplantation: a collaborative transplant study report","volume":"12","author":"Opelz","year":"2012","journal-title":"Am J Transplant"},{"key":"key20160823140406748_ref1-bib177","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1111\/ajt.12313","article-title":"Association between steroid dosage and death with a functioning graft after kidney transplantation","volume":"13","author":"Opelz","year":"2013","journal-title":"Am J Transplant"},{"key":"key20160823140406748_ref1-bib178","doi-asserted-by":"publisher","first-page":"814","DOI":"10.2215\/CJN.04681107","article-title":"Impact of acute rejection and new-onset diabetes on long-term transplant graft and patient survival","volume":"3","author":"Cole","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"key20160823140406748_ref1-bib179","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1097\/TP.0b013e31827a938f","article-title":"Risks and benefits of preemptive second kidney transplantation","volume":"95","author":"Johnston","year":"2013","journal-title":"Transplantation"},{"key":"key20160823140406748_ref1-bib180","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1046\/j.1523-1755.2002.00424.x","article-title":"Post-transplant renal function in the first year predicts long-term kidney transplant survival","volume":"62","author":"Hariharan","year":"2002","journal-title":"Kidney Int"},{"key":"key20160823140406748_ref1-bib181","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1053\/ajkd.2002.31996","article-title":"A thirty per cent chronic decline in inverse serum creatinine is an excellent predictor of late renal allograft failure","volume":"39","author":"Kasiske","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"key20160823140406748_ref1-bib182","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.jval.2014.01.001","article-title":"Projecting long-term graft and patient survival after transplantation","volume":"17","author":"Levy","year":"2014","journal-title":"Value Health"},{"key":"key20160823140406748_ref1-bib183","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1097\/01.TP.0000061602.03327.E2","article-title":"Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation","volume":"75","author":"Meier-Kriesche","year":"2003","journal-title":"Transplantation"},{"key":"key20160823140406748_ref1-bib184","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1097\/01.tp.0000188135.04259.2e","article-title":"Estimated one-year glomerular filtration rate is the best predictor of long-term graft function following renal transplant","volume":"81","author":"Salvadori","year":"2006","journal-title":"Transplantation"},{"key":"key20160823140406748_ref1-bib185","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/j.1399-3046.2008.00976.x","article-title":"Estimated one-yr glomerular filtration rate is an excellent predictor of long-term graft survival in pediatric first kidney transplants","volume":"13","author":"Muscheites","year":"2009","journal-title":"Pediatr Transplant"},{"key":"key20160823140406748_ref1-bib186","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1034\/j.1399-3046.2000.00091.x","article-title":"The impact of acute rejection on chronic rejection: a report of the North American Pediatric Renal Transplant Cooperative Study","volume":"4","author":"Tejani","year":"2000","journal-title":"Pediatr Transplant"},{"key":"key20160823140406748_ref1-bib187","volume-title":"Estimating Long-term Kidney Graft and Patient Survival Estimates Using Period Analysis","author":"Hudson","year":"2014"},{"key":"key20160823140406748_ref1-bib188","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1034\/j.1600-6143.2003.00082.x","article-title":"Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients","volume":"3","author":"Woodward","year":"2003","journal-title":"Am J Transplant"},{"key":"key20160823140406748_ref1-bib189","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1097\/TP.0b013e3181734b4a","article-title":"Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab\/thymoglobulin: one year follow-up","volume":"86","author":"Ciancio","year":"2008","journal-title":"Transplantation"},{"key":"key20160823140406748_ref1-bib190","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/2047-1440-2-14","article-title":"Efficacy and safety of concentration-controlled everolimus with reduced-dose cyclosporine in Japanese de novo renal transplant patients: 12-month results","volume":"2","author":"Takahashi","year":"2013","journal-title":"Transplantation Res"},{"key":"key20160823140406748_ref1-bib191","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1111\/j.1600-6143.2010.03129.x","article-title":"Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients","volume":"10","author":"Tedesco-Silva","year":"2010","journal-title":"Am J Transplant"},{"key":"key20160823140406748_ref1-bib192","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1097\/01.tp.0000173378.28790.0b","article-title":"Comparison of steroid avoidance in tacrolimus\/mycophenolate mofetil and tacrolimus\/sirolimus combination in kidney transplantation monitored by surveillance biopsy","volume":"80","author":"Anil Kumar","year":"2005","journal-title":"Transplantation"},{"key":"key20160823140406748_ref1-bib193","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1097\/01.TP.0000062837.99400.60","article-title":"Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months","volume":"75","author":"Gonwa","year":"2003","journal-title":"Transplantation"},{"key":"key20160823140406748_ref1-bib194","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1399-0012.2007.00756.x","article-title":"Mycophenolate mofetil vs. sirolimus in kidney transplant recipients receiving tacrolimus-based immunosuppressive regimen","volume":"22","author":"Sampaio","year":"2008","journal-title":"Clinical Transplantation"},{"key":"key20160823140406748_ref1-bib195","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/S0002-9610(99)00042-2","article-title":"A prospective randomized trial comparing the efficacy of tacrolimus versus cyclosporine in black recipients of primary cadaveric renal transplants","volume":"177","author":"Raofi","year":"1999","journal-title":"Am J Surg"},{"key":"key20160823140406748_ref1-bib196","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1097\/TP.0b013e318296c9d5","article-title":"Comparison of pharmacokinetics and pathology for low-dose tacrolimus once-daily and twice-daily in living kidney transplantation: prospective trial in once-daily versus twice-daily tacrolimus","volume":"96","author":"Tsuchiya","year":"2013","journal-title":"Transplantation"},{"key":"key20160823140406748_ref1-bib197","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1056\/NEJMoa050085","article-title":"Costimulation blockade with belatacept in renal transplantation","volume":"353","author":"Vincenti","year":"2005","journal-title":"N Engl J Med"},{"key":"key20160823140406748_ref1-bib198","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1111\/j.1600-6143.2009.03005.x","article-title":"A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study)","volume":"10","author":"Vincenti","year":"2010","journal-title":"Am J Transplant"},{"key":"key20160823140406748_ref1-bib199","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1111\/j.1600-6143.2010.03016.x","article-title":"A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study)","volume":"10","author":"Durrbach","year":"2010","journal-title":"Am J Transplant"},{"key":"key20160823140406748_ref1-bib200","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1111\/j.1600-6143.2009.02615.x","article-title":"Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study","volume":"9","author":"Lebranchu","year":"2009","journal-title":"Am J Transplant"},{"key":"key20160823140406748_ref1-bib201","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.1111\/j.1600-6143.2007.01976.x","article-title":"Sirolimus versus cyclosporine in kidney recipients receiving thymoglobulin, mycophenolate mofetil and a 6-month course of steroids","volume":"7","author":"B\u00fcchler","year":"2007","journal-title":"Am J Transplant"},{"key":"key20160823140406748_ref1-bib202","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1097\/00007890-200004150-00009","article-title":"Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients","volume":"69","author":"Kreis","year":"2000","journal-title":"Transplantation"},{"key":"key20160823140406748_ref1-bib203","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1097\/TP.0b013e3181e11798","article-title":"Renal function, efficacy, and safety of sirolimus and mycophenolate mofetil after short-term calcineurin inhibitor-based quadruple therapy in de novo renal transplant patients: one-year analysis of a randomized multicenter trial","volume":"90","author":"Guba","year":"2010","journal-title":"Transplantation"},{"key":"key20160823140406748_ref1-bib204","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1097\/01.tp.0000235823.09788.f6","article-title":"Living related kidney transplantation without calcineurin inhibitors: initial experience in a Mexican center","volume":"82","author":"Martinez-Mier","year":"2006","journal-title":"Transplantation"},{"key":"key20160823140406748_ref1-bib205","doi-asserted-by":"publisher","first-page":"3466","DOI":"10.1016\/j.transproceed.2006.10.098","article-title":"Short-term results under three different immunosuppressive regimens at one center","volume":"38","author":"Schaefer","year":"2006","journal-title":"Transplant Proc"},{"key":"key20160823140406748_ref1-bib206","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1097\/00007890-199904150-00017","article-title":"Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group","volume":"67","author":"Groth","year":"1999","journal-title":"Transplantation"},{"key":"key20160823140406748_ref1-bib207","doi-asserted-by":"publisher","first-page":"CD003961","DOI":"10.1002\/14651858.cd003961.pub2","article-title":"Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients","volume":"19","author":"Webster","journal-title":"Cochrane Database System Rev"},{"key":"key20160823140406748_ref1-bib208","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1097\/01.TP.0000141094.34903.54","article-title":"Everolimus (certican) 12-month safety and efficacy versus mycophenolate mofetil in de Novo renal transplant recipients","volume":"78","author":"Vitko","year":"2004","journal-title":"Transplantation"},{"key":"key20160823140406748_ref1-bib209","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/nep.12004","article-title":"Enteric-coated mycophenolate sodium in combination with full dose or reduced dose cyclosporine, basiliximab and corticosteroids in Australian de novo kidney transplant patients","volume":"18","author":"Chadban","year":"2013","journal-title":"Nephrology"},{"key":"key20160823140406748_ref1-bib210","doi-asserted-by":"publisher","first-page":"2744","DOI":"10.1111\/j.1600-6143.2012.04162.x","article-title":"Improved renal function after early conversion from a calcineurin inhibitor to everolimus: a randomized trial in kidney transplantation","volume":"12","author":"Mj\u00f6rnstedt","year":"2012","journal-title":"Am J Transplant"},{"key":"key20160823140406748_ref1-bib211","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1097\/00007890-200210270-00002","article-title":"Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporin","volume":"74","author":"Flechner","year":"2002","journal-title":"Transplantation"},{"key":"key20160823140406748_ref1-bib212","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1111\/petr.12115","article-title":"Cytomegalovirus prophylaxis in pediatric kidney transplantation: the Dutch experience","volume":"17","author":"Jongsma","year":"2013","journal-title":"Pediatr Transplant"},{"key":"key20160823140406748_ref1-bib213","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1093\/ndt\/gft429","article-title":"Dyslipidaemia in children on renal replacement therapy","volume":"29","author":"Bonthuis","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"key20160823140406748_ref1-bib214","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1034\/j.1600-6143.2003.00133.x","article-title":"Prevalence and management of anemia in renal transplant recipients: a European survey","volume":"3","author":"Vanrenterghem","year":"2003","journal-title":"Am J Transplant"},{"key":"key20160823140406748_ref1-bib215","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1097\/TP.0b013e3181c7dc99","article-title":"Factors affecting graft and patient survival after live donor kidney transplantation in the UK","volume":"89","author":"Fuggle","year":"2010","journal-title":"Transplantation"},{"key":"key20160823140406748_ref1-bib216","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/S0140-6736(10)60827-6","article-title":"Analysis of factors that affect outcome after transplantation of kidneys donated after cardiac death in the UK: a cohort study","volume":"376","author":"Summers","year":"2010","journal-title":"Lancet"},{"key":"key20160823140406748_ref1-bib217","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s11136-010-9648-y","article-title":"Development of the EQ-5D-Y: a child-friendly version of the EQ-5D","volume":"19","author":"Wille","year":"2010","journal-title":"Qual Life Res"},{"key":"key20160823140406748_ref1-bib218","volume-title":"Health Survey for England 2012","author":"Health and Social Care Information Centre","year":"2013"},{"key":"key20160823140406748_ref1-bib219","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1111\/j.1524-4733.2010.00700.x","article-title":"Populating an economic model with health state utility values: moving toward better practice","volume":"13","author":"Ara","year":"2010","journal-title":"Value Health"},{"key":"key20160823140406748_ref1-bib220","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1111\/j.1524-4733.2007.00308.x","article-title":"Preference-based quality of life of patients on renal replacement therapy: a systematic review and meta-analysis","volume":"11","author":"Liem","year":"2008","journal-title":"Value Health"},{"key":"key20160823140406748_ref1-bib221","doi-asserted-by":"publisher","first-page":"341","DOI":"10.5414\/CNP60341","article-title":"Quality of life in patients treated with hemodialysis or peritoneal dialysis: what are the important determinants?","volume":"60","author":"Manns","year":"2003","journal-title":"Clinical nephrology"},{"issue":"24","key":"key20160823140406748_ref1-bib222","doi-asserted-by":"publisher","DOI":"10.3310\/hta9240","article-title":"An evaluation of the costs, effectiveness and quality of renal replacement therapy provision in renal satellite units in England and Wales","volume":"9","author":"Roderick","year":"2005","journal-title":"Health Technol Assess"},{"key":"key20160823140406748_ref1-bib223","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1177\/089686080202200107","article-title":"Comparison of hemodialysis and peritoneal dialysis --a cost-utility analysis","volume":"22","author":"Sennfalt","year":"2002","journal-title":"Peritoneal Dialysis International"},{"key":"key20160823140406748_ref1-bib224","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1093\/ndt\/gfh175","article-title":"Quality of life on chronic dialysis: comparison between haemodialysis and peritoneal dialysis","volume":"19","author":"Wasserfallen","year":"2004","journal-title":"Nephrology Dialysis Transplantation"},{"key":"key20160823140406748_ref1-bib225","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1097\/01.TP.0000072807.46212.FA","article-title":"Health professionals\u2019 perceptions of health status after renal transplantation: a comparison with transplantation candidates\u2019 expectations","volume":"76","author":"Cleemput","year":"2003","journal-title":"Transplantation"},{"key":"key20160823140406748_ref1-bib226","first-page":"147","article-title":"Socio-economic evaluation of kidney-transplantation in Germany","volume":"18","author":"Greiner","year":"2001","journal-title":"Arch Hellenic Med"},{"key":"key20160823140406748_ref1-bib227","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1111\/j.1432-2277.2003.tb00366.x","article-title":"Health-related quality of life and symptom experience in tacrolimus-based regimens after renal transplantation: a multicentre study","volume":"16","author":"Moons","year":"2003","journal-title":"Transplant International"},{"key":"key20160823140406748_ref1-bib228","doi-asserted-by":"publisher","first-page":"E554","DOI":"10.1111\/ctr.12198","article-title":"Health-related quality of life in kidney transplant patients with diabetes","volume":"27","author":"Dukes","year":"2013","journal-title":"Clin Transplant"},{"key":"key20160823140406748_ref1-bib229","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1097\/00005650-200503000-00003","article-title":"US valuation of the EQ-5D health states: development and testing of the D1 valuation model","volume":"43","author":"Shaw","year":"2005","journal-title":"Med Care"},{"key":"key20160823140406748_ref1-bib230","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1097\/00005650-200503000-00004","article-title":"Valuations of EQ-5D health states: are the United States and United Kingdom different?","volume":"43","author":"Johnson","year":"2005","journal-title":"Med Care"},{"key":"key20160823140406748_ref1-bib231","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.diabres.2004.01.002","article-title":"The financial costs of hospital care for people with diabetes who have single and multiple macrovascular complications","volume":"67","author":"Currie","year":"2005","journal-title":"Diabetes Res Clin Pract"},{"key":"key20160823140406748_ref1-bib232","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1111\/j.1524-4733.2005.00046.x","article-title":"The routine collation of health outcomes data from hospital treated subjects in the Health Outcomes Data Repository (HODaR): descriptive analysis from the first 20,000 subjects","volume":"8","author":"Currie","year":"2005","journal-title":"Value Health"},{"key":"key20160823140406748_ref1-bib233","doi-asserted-by":"publisher","first-page":"e1001307","DOI":"10.1371\/journal.pmed.1001307","article-title":"A systematic review and meta-analysis of utility-based quality of life in chronic kidney disease treatments","volume":"9","author":"Wyld","year":"2012","journal-title":"PLOS Med"},{"key":"key20160823140406748_ref1-bib234","volume-title":"Unit Costs of Health and Social Care 2014","author":"Curtis","year":"2014"},{"key":"key20160823140406748_ref1-bib235","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1056\/NEJMoa060068","article-title":"Rabbit antithymocyte globulin versus basiliximab in renal transplantation","volume":"355","author":"Brennan","year":"2006","journal-title":"N Engl J Med"},{"key":"key20160823140406748_ref1-bib236","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.trim.2008.08.005","article-title":"Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes","volume":"20","author":"Anil Kumar","year":"2008","journal-title":"Transplant Immunology"},{"key":"key20160823140406748_ref1-bib237","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1111\/j.1600-6143.2009.02794.x","article-title":"Pharmacokinetics for once- versus twice-daily tacrolimus formulations in de novo kidney transplantation: a randomized, open-label trial","volume":"9","author":"Wlodarczyk","year":"2009","journal-title":"Am J Transplant"},{"key":"key20160823140406748_ref1-bib238","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.3349\/ymj.2014.55.5.1341","article-title":"Safety and efficacy of conversion from twice-daily tacrolimus to once-daily tacrolimus one month after transplantation: randomized controlled trial in adult renal transplantation","volume":"55","author":"Oh","year":"2014","journal-title":"Yonsei Med J"},{"key":"key20160823140406748_ref1-bib239","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1681\/ASN.2005030249","article-title":"No difference in degree of interstitial Sirius red-stained area in serial biopsies from area under concentration-over-time curves-guided cyclosporine versus tacrolimus-treated renal transplant recipients at one year","volume":"17","author":"Rowshani","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"key20160823140406748_ref1-bib240","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1097\/TP.0b013e31824215b7","article-title":"A randomized trial with steroids and antithymocyte globulins comparing cyclosporine\/azathioprine versus tacrolimus\/mycophenolate mofetil (CATM2) in renal transplantation","volume":"93","author":"Vacher-Coponat","year":"2012","journal-title":"Transplantation"},{"key":"key20160823140406748_ref1-bib241","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/01.TP.0000164352.65613.24","article-title":"Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study","volume":"80","author":"Lorber","year":"2005","journal-title":"Transplantation"},{"key":"key20160823140406748_ref1-bib242","doi-asserted-by":"crossref","DOI":"10.1159\/000360021","volume-title":"UK Renal Registry 16th Annual Report: chapter 2 UK RRT Prevalence in 2012: national and Centre-Specific Analyses","author":"Shaw","year":"2013"},{"key":"key20160823140406748_ref1-bib243","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1111\/j.1600-6143.2010.03074.x","article-title":"The efficacy and safety of 200 days Valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients","volume":"10","author":"Humar","year":"2010","journal-title":"Am J Transplant"},{"key":"key20160823140406748_ref1-bib244","volume-title":"Kidney Transplant Protocol","author":"Moore","year":"2012"},{"key":"key20160823140406748_ref1-bib245","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1093\/cid\/cis823","article-title":"Epidemiology and morbidity of Epstein\u2013Barr virus infection in pediatric renal transplant recipients: a multicenter, prospective study","volume":"56","author":"Hocker","year":"2013","journal-title":"Clin Infect Dis"},{"key":"key20160823140406748_ref1-bib246","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1111\/j.1600-6143.2012.04084.x","article-title":"Dyslipidemia and its therapeutic challenges in renal transplantation","volume":"12","author":"Riella","year":"2012","journal-title":"Am J Transplant"},{"key":"key20160823140406748_ref1-bib247","volume-title":"Reference Costs Guidance 2013\u201314","author":"Department of Health"},{"key":"key20160823140406748_ref1-bib248","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/dme.12647","article-title":"The impact of diabetes-related complications on healthcare costs: new results from the UKPDS (UKPDS 84)","volume":"32","author":"Alva","year":"2015","journal-title":"Diabet Med"},{"key":"key20160823140406748_ref1-bib249","volume-title":"Belatacept Micro-Costing Model \u2013 UK","author":"Ling","year":"2011"},{"key":"key20160823140406748_ref1-bib250","first-page":"S25","article-title":"Hypertension and obesity after pediatric kidney transplantation: management based on pathophysiology: a mini review","volume":"5","author":"John","year":"2014","journal-title":"Int J Prev Med"},{"key":"key20160823140406748_ref1-bib251","volume-title":"Developing Robust Reference Costs for Kidney Transplants \u2013 Update","author":"NHS Kidney Care","year":"2011"},{"key":"key20160823140406748_ref1-bib252","volume-title":"Provider to Provider Services 2013\u20132014 Tariff","author":"University College London Hospitals NHS Foundation Trust"},{"key":"key20160823140406748_ref1-bib253","volume-title":"HRG4\u2009+\u2009Reference Costs Code to Group","author":"National Casemix Office","year":"2014"},{"key":"key20160823140406748_ref1-bib254","volume-title":"National Organ Retrieval Service: service Evaluation","author":"NHS Blood and Transplant","year":"2013"},{"issue":"21","key":"key20160823140406748_ref1-bib255","doi-asserted-by":"publisher","DOI":"10.3310\/hta9210","article-title":"Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study","volume":"9","author":"Woodroffe","year":"2005","journal-title":"Health Technol Assess"},{"key":"key20160823140406748_ref1-bib256","volume-title":"Guide to the Methods of Technology Appraisal","author":"NICE","year":"2004"},{"key":"key20160823140406748_ref1-bib257","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/S0140-6736(00)02480-6","article-title":"Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group","volume":"356","author":"Kahan","year":"2000","journal-title":"Lancet"},{"key":"key20160823140406748_ref1-bib258","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/j.1399-0012.2004.00113.x","article-title":"An open-label randomized trial of the safety and efficacy of sirolimus vs. azathioprine in living related renal allograft recipients receiving cyclosporine and prednisone combination","volume":"18","author":"Machado","year":"2004","journal-title":"Clin Transplant"},{"key":"key20160823140406748_ref1-bib259","doi-asserted-by":"publisher","first-page":"37S","DOI":"10.1016\/S0041-1345(03)00353-1","article-title":"Two-year results of multicenter phase III trials on the effect of the addition of sirolimus to cyclosporine-based immunosuppressive regimens in renal transplantation","volume":"35","author":"Kahan","year":"2003","journal-title":"Transplant Proc"},{"key":"key20160823140406748_ref1-bib260","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.3390\/ph6101170","article-title":"Safety of immunosuppressive drugs used as maintenance therapy in kidney transplantation: a systematic review and meta-analysis","volume":"6","author":"Almeida","year":"2013","journal-title":"Pharmaceuticals"},{"key":"key20160823140406748_ref1-bib261","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1097\/TP.0b013e3182708e56","article-title":"Is cytomegalovirus prophylaxis dispensable in patients receiving an mTOR inhibitor-based immunosuppression? A systematic review and meta-analysis","volume":"94","author":"Andrassy","year":"2012","journal-title":"Transplantation"},{"key":"key20160823140406748_ref1-bib262","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1007\/s00467-010-1595-x","article-title":"Systematic review of randomized controlled trial quality in pediatric kidney transplantation","volume":"25","author":"Brooks","year":"2010","journal-title":"Pediatric Nephrology"},{"key":"key20160823140406748_ref1-bib263","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1097\/TP.0b013e318284c15b","article-title":"Once-daily extended-release versus twice-daily standard-release tacrolimus in kidney transplant recipients: a systematic review","volume":"95","author":"Ho","year":"2013","journal-title":"Transplantation"},{"key":"key20160823140406748_ref1-bib264","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1111\/j.1600-6143.2008.02272.x","article-title":"Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients","volume":"8","author":"Kasiske","year":"2008","journal-title":"Am J Transplant"},{"key":"key20160823140406748_ref1-bib265","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1097\/TP.0b013e3181952623","article-title":"Mycophenolate mofetil decreases acute rejection and may improve graft survival in renal transplant recipients when compared with azathioprine: a systematic review","volume":"87","author":"Knight","year":"2009","journal-title":"Transplantation"},{"key":"key20160823140406748_ref1-bib266","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1016\/j.transproceed.2010.02.088","article-title":"Basiliximab or antithymocyte globulin for induction therapy in kidney transplantation: a meta-analysis","volume":"42","author":"Liu","year":"2010","journal-title":"Transplant Proc"},{"key":"key20160823140406748_ref1-bib267","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.cd010699.pub2","article-title":"Belatacept for kidney transplant recipients","volume":"11","author":"Masson","year":"2014","journal-title":"Cochrane Database System Rev"},{"key":"key20160823140406748_ref1-bib268","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1097\/TP.0b013e318195a421","article-title":"Calcineurin inhibitor sparing with mycophenolate in kidney transplantation: a systematic review and meta-analysis","volume":"87","author":"Moore","year":"2009","journal-title":"Transplantation"},{"key":"key20160823140406748_ref1-bib269","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1097\/01.tp.0000237101.58974.43","article-title":"Conversion from calcineurin inhibitors to sirolimus for chronic renal allograft dysfunction: a systematic review of the evidence","volume":"82","author":"Mulay","year":"2006","journal-title":"Transplantation"},{"key":"key20160823140406748_ref1-bib270","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.trre.2013.06.001","article-title":"Review of combination therapy with mTOR inhibitors and tacrolimus minimization after transplantation","volume":"27","author":"Peddi","year":"2013","journal-title":"Transplant Rev"},{"key":"key20160823140406748_ref1-bib271","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1111\/j.1432-2277.2011.01357.x","article-title":"Do wound complications or lymphoceles occur more often in solid organ transplant recipients on mTOR inhibitors? A systematic review of randomized controlled trials","volume":"24","author":"Pengel","year":"2011","journal-title":"Transpl Int"},{"key":"key20160823140406748_ref1-bib272","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1345\/aph.1p456","article-title":"Impact of mycophenolate mofetil dose reduction on allograft outcomes in kidney transplant recipients on tacrolimus-based regimens: a systematic review","volume":"45","author":"Su","year":"2011","journal-title":"Ann Pharmacother"},{"key":"key20160823140406748_ref1-bib273","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1097\/01.TP.0000109643.32659.C4","article-title":"Interleukin 2 receptor antagonists for renal transplantation recipients: a meta-analysis of randomized trials","volume":"77","author":"Webster","year":"2004","journal-title":"Transplantation"},{"key":"key20160823140406748_ref1-bib274","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.cd003897.pub2","volume":"1","author":"Webster","year":"2004","journal-title":". Cochrane Database System Rev"},{"key":"key20160823140406748_ref1-bib275","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1136\/bmj.38569.471007.AE","article-title":"Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data","volume":"331","author":"Webster","year":"2005","journal-title":"BMJ"},{"key":"key20160823140406748_ref1-bib276","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1097\/01.tp.0000219703.39149.85","article-title":"Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials","volume":"81","author":"Webster","year":"2006","journal-title":"Transplantation"},{"key":"key20160823140406748_ref1-bib277","doi-asserted-by":"publisher","first-page":"CD003897","DOI":"10.1002\/14651858.cd003897.pub3","article-title":"Interleukin 2 receptor antagonists for kidney transplant recipients","volume":"1","author":"Webster","year":"2010","journal-title":"Cochrane Database System Rev"},{"key":"key20160823140406748_ref1-bib278","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1016\/j.transproceed.2014.02.010","article-title":"Calcineurin inhibitor avoidance and withdrawal for kidney transplantation: a systematic review and meta-analysis of randomized controlled trials","volume":"46","author":"Yan","year":"2014","journal-title":"Transplant Proc"},{"key":"key20160823140406748_ref1-bib279","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3346\/jkms.2012.27.4.337","article-title":"Prospective controlled protocol for three months steroid withdrawal with tacrolimus, basiliximab, and mycophenolate mofetil in renal transplant recipients","volume":"27","author":"Oh","year":"2012","journal-title":"J Korean Med Sci"},{"key":"key20160823140406748_ref1-bib280","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/j.1600-6143.2009.02767.x","article-title":"A randomized double-blind, placebo controlled trial of steroid withdrawal after pediatric renal transplantation","volume":"10","author":"Benfield","year":"2010","journal-title":"Am J Transplant"},{"key":"key20160823140406748_ref1-bib281","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1097\/TP.0b013e318291a269","article-title":"A randomized, open-label study of sirolimus versus cyclosporine in primary de novo renal allograft recipients","volume":"95","author":"Flechner","year":"2013","journal-title":"Transplantation"},{"key":"key20160823140406748_ref1-bib282","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1111\/j.1600-6143.2012.04145.x","article-title":"Complete steroid avoidance is effective and safe in children with renal transplants: a multicenter randomized trial with three-year follow-up","volume":"12","author":"Sarwal","year":"2012","journal-title":"Am J Transplant"},{"key":"key20160823140406748_ref1-bib283","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1097\/TP.0b013e318186f98a","article-title":"Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial","volume":"86","author":"Gelder","year":"2008","journal-title":"Transplantation"},{"key":"key20160823140406748_ref1-bib284","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1097\/01.tp.0000260146.57898.9c","article-title":"Maintenance immunosuppression with mycophenolate mofetil and corticosteroids in pediatric kidney transplantation: temporary benefit but not without risk","volume":"83","author":"Cransberg","year":"2007","journal-title":"Transplantation"},{"key":"key20160823140406748_ref1-bib285","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1056\/NEJM199801153380304","article-title":"Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group","volume":"338","author":"Vincenti","year":"1998","journal-title":"N Engl J Med"},{"key":"key20160823140406748_ref1-bib286","doi-asserted-by":"publisher","first-page":"S261","DOI":"10.1097\/00007890-200004271-00577","article-title":"Three year outcome of the phase III clinical trials with Daclizumab","volume":"69","author":"Vincenti","year":"2000","journal-title":"Transplantation"},{"key":"key20160823140406748_ref1-bib287","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1097\/00007890-199907270-00028","article-title":"Cytomegalovirus infections after treatment with daclizumab, an anti IL-2 receptor antibody, for prevention of renal allograft rejection","volume":"68","author":"Hengster","year":"1999","journal-title":"Transplantation"},{"key":"key20160823140406748_ref1-bib288","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1097\/00007890-200109150-00017","article-title":"Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation","volume":"72","author":"Bumgardner","year":"2001","journal-title":"Transplantation"},{"key":"key20160823140406748_ref1-bib289","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/S0041-1345(00)02307-1","article-title":"Basiliximab significantly reduces acute rejection in renal transplant patients given triple therapy with azathioprine","volume":"33","author":"Ponticelli","year":"2001","journal-title":"Transplant Proc"},{"key":"key20160823140406748_ref1-bib290","doi-asserted-by":"publisher","first-page":"3209","DOI":"10.1016\/S0041-1345(01)02366-1","article-title":"Low rate of acute rejection and cytomegalovirus infection in kidney transplant recipients with basiliximab","volume":"33","author":"Folkmane","year":"2001","journal-title":"Transplant Proc"},{"key":"key20160823140406748_ref1-bib291","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/S0041-1345(01)02845-7","article-title":"Results of renal transplantation with different immunosuppressive regimens","volume":"34","author":"Folkmane","year":"2002","journal-title":"Transplant Proc"},{"key":"key20160823140406748_ref1-bib292","first-page":"3065","article-title":"FK 506 in clinical kidney transplantation","volume":"23","author":"Shapiro","year":"1991","journal-title":"Transplant Proc"},{"key":"key20160823140406748_ref1-bib293","doi-asserted-by":"publisher","first-page":"27S","DOI":"10.1016\/S0041-1345(99)00789-7","article-title":"Four-year follow-up of the European Tacrolimus Multicenter Renal Study","volume":"31","author":"Mayer","year":"1999","journal-title":"Transplant Proc"},{"key":"key20160823140406748_ref1-bib294","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/S0041-1345(02)02942-1","article-title":"Chronic rejection and graft half-life: five-year follow-up of the European Tacrolimus Multicenter Renal Study","volume":"34","author":"Mayer","year":"2002","journal-title":"Transplant Proc"},{"key":"key20160823140406748_ref1-bib295","first-page":"238","article-title":"Tacrolimus vs cyclosporin in renal transplantation: five-year follow-up of the European Multicentre Study","volume":"2","author":"Mayer","year":"2002","journal-title":"Am J Transplant"},{"key":"key20160823140406748_ref1-bib296","doi-asserted-by":"publisher","first-page":"64S","DOI":"10.1016\/S0041-1345(99)00798-8","article-title":"Immunological and nonimmunological risk factors with tacrolimus and Neoral in renal transplant recipients: an interim report","volume":"31","author":"Jurewicz","year":"1999","journal-title":"Transplant Proc"},{"key":"key20160823140406748_ref1-bib297","doi-asserted-by":"publisher","first-page":"i7","DOI":"10.1093\/ndt\/gfg1028","article-title":"Tacrolimus versus ciclosporin immunosuppression: long-term outcome in renal transplantation","volume":"18","author":"Jurewicz","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"key20160823140406748_ref1-bib298","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/S0041-1345(00)02477-5","article-title":"A large, multicentre trial to compare the efficacy and safety of tacrolimus with cyclosporine microemulsion following renal transplantation","volume":"33","author":"Sperschneider","year":"2001","journal-title":"Transplant Proc"},{"key":"key20160823140406748_ref1-bib299","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1034\/j.1600-6143.2003.00156.x","article-title":"Cardiovascular risk factors and estimated risk for CAD in a randomized trial comparing calcineurin inhibitors in renal transplantation","volume":"3","author":"Kr\u00e4mer","year":"2003","journal-title":"Am J Transplant"},{"key":"key20160823140406748_ref1-bib300","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1016\/S0041-1345(02)02969-X","article-title":"Oral dosing of tacrolimus and cyclosporine microemulsion \u2013 Results from a large multicenter study in renal transplantation","volume":"34","author":"Dietl","year":"2002","journal-title":"Transplant Proc"},{"key":"key20160823140406748_ref1-bib301","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.transproceed.2003.11.056","article-title":"Comparison of tacrolimus and cyclosporin in renal transplantation by the protocol biopsies","volume":"36","author":"T\u00f6z","year":"2004","journal-title":"Transplant Proc"},{"key":"key20160823140406748_ref1-bib302","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1002\/bjs.4134","article-title":"Randomized clinical trial of the effect of microemulsion cyclosporin and tacrolimus on renal allograft fibrosis","volume":"90","author":"Murphy","year":"2003","journal-title":"Br J Surg"},{"key":"key20160823140406748_ref1-bib303","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1097\/00007890-199806150-00007","article-title":"A blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation: results at three years. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group","volume":"65","author":"Mathew","year":"1998","journal-title":"Transplantation"},{"key":"key20160823140406748_ref1-bib304","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1016\/S0041-1345(02)02863-4","article-title":"Effect of mycophenolate mofetil on the prevention of acute renal allograft rejection","volume":"34","author":"Miladipour","year":"2002","journal-title":"Transplant Proc"},{"key":"key20160823140406748_ref1-bib305","first-page":"262","article-title":"Changes in health-related quality of life in the first year of kidney transplantation","volume":"22","author":"Baltar","year":"2002","journal-title":"Nefrologia"},{"key":"key20160823140406748_ref1-bib306","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1046\/j.1600-6143.2003.00337.x","article-title":"Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients","volume":"4","author":"Salvadori","year":"2004","journal-title":"Am J Transplant"},{"key":"key20160823140406748_ref1-bib307","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1097\/00007890-200109150-00007","article-title":"Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure","volume":"72","author":"Johnson","year":"2001","journal-title":"Transplantation"},{"key":"key20160823140406748_ref1-bib308","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1016\/j.transproceed.2003.09.036","article-title":"Cyclosporine microemulsion (Neoral) versus tacrolimus (FK506) as maintenance therapy in kidney transplant patients","volume":"35","author":"Abou-Jaoude","year":"2003","journal-title":"Transplant Proc"},{"key":"key20160823140406748_ref1-bib309","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1016\/j.transproceed.2005.08.040","article-title":"Tacrolimus (FK506) versus cyclosporine microemulsion (neoral) as maintenance immunosuppression therapy in kidney transplant recipients","volume":"37","author":"Abou-Jaoude","year":"2005","journal-title":"Transplant Proc"},{"key":"key20160823140406748_ref1-bib310","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1016\/S0041-1345(00)02471-4","article-title":"Canadian multicentre trial of tacrolimus\/azathioprine\/steroids versus tacrolimus\/mycophenolate mofetil\/steroids versus neoral\/mycophenolate mofetil\/steroids in renal transplantation","volume":"33","author":"Busque","year":"2001","journal-title":"Transplant Proc"},{"key":"key20160823140406748_ref1-bib311","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1097\/00007890-200003150-00028","article-title":"Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation","volume":"69","author":"Johnson","year":"2000","journal-title":"Transplantation"},{"key":"key20160823140406748_ref1-bib312","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1016\/S0041-1345(03)00576-1","article-title":"Tacrolimus-basiliximab versus cyclosporine-basiliximab in renal transplantation \u2018de novo\u2019: acute rejection and complications","volume":"35","author":"Garcia","year":"2003","journal-title":"Transplant Proc"},{"key":"key20160823140406748_ref1-bib313","first-page":"1","article-title":"Neoral\u00ae in cadaveric renal transplantation: 189 patients with a minimum 1-year follow up","volume":"87","author":"Morris-Stiff","year":"2000","journal-title":"Br J Surg"},{"key":"key20160823140406748_ref1-bib314","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1111\/j.1600-6143.2007.01749.x","article-title":"Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus","volume":"7","author":"Vincenti","year":"2007","journal-title":"Am J Transplant"},{"key":"key20160823140406748_ref1-bib315","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1016\/S0041-1345(00)01408-1","article-title":"Tacrolimus vs CyA Neoral in combination with MMF and steroids after cadaveric renal transplantation","volume":"32","author":"Wang","year":"2000","journal-title":"Transplant Proc"},{"key":"key20160823140406748_ref1-bib316","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/S0041-1345(00)00910-6","article-title":"Randomized trial comparing neoral and tacrolimus immunosuppression for recipients of renal transplants procured from different donor groups","volume":"32","author":"White","year":"2000","journal-title":"Transplant Proc"},{"key":"key20160823140406748_ref1-bib317","first-page":"008","article-title":"A randomised trial comparing Neoral (ciclosporin) and tacrolimus immunosuppression for recipients of renal transplants procured from different donor groups","volume":"86","author":"Williams","year":"1999","journal-title":"Br J Surg"},{"key":"key20160823140406748_ref1-bib318","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1111\/j.1600-6143.2011.03573.x","article-title":"The ORION study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients","volume":"11","author":"Flechner","year":"2011","journal-title":"Am J Transplant"},{"key":"key20160823140406748_ref1-bib319","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1111\/j.1600-6143.2005.01177.x","article-title":"Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus","volume":"6","author":"Larson","year":"2006","journal-title":"Am J Transplant"},{"key":"key20160823140406748_ref1-bib320","doi-asserted-by":"publisher","first-page":"613","DOI":"10.5301\/JN.2011.6247","article-title":"Good outcomes with cyclosporine very low exposure with everolimus high exposure in renal transplant patients","volume":"24","author":"Bertoni","year":"2011","journal-title":"J Nephrol"},{"key":"key20160823140406748_ref1-bib321","first-page":"1131","article-title":"A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (Neoral) and sirolimus in renal transplantation. 1. Drug interactions and rejection at one year","volume":"77","author":"Ciancio","year":"2004","journal-title":"Transplantation"},{"key":"key20160823140406748_ref1-bib322","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1097\/01.tp.0000167757.63922.42","article-title":"A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 1 year","volume":"80","author":"Mendez","year":"2005","journal-title":"Transplantation"}],"container-title":["Health Technology Assessment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/publications\/hta20610\/hta20610.xml","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2002525","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/publications\/hta20610\/hta20610.xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2003442","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T01:27:57Z","timestamp":1718760477000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/hta\/hta20610\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":322,"journal-issue":{"issue":"61","published-online":{"date-parts":[[2016,8]]}},"alternative-id":["10.3310\/hta20610"],"URL":"https:\/\/doi.org\/10.3310\/hta20610","relation":{},"ISSN":["1366-5278","2046-4924"],"issn-type":[{"value":"1366-5278","type":"print"},{"value":"2046-4924","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"This content has been made freely available to all.","name":"free","label":"Free to read"}]}}